Sugi Predict

Sugi Predict / Compounds / SCHEMBL4620642

SCHEMBL4620642

SCHEMBL4620642

Nc1ncc2ccccc2[n+]1[O-]

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.48
▸ PDPK1 O15530 1/20 0.41
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ BCL2 P10415 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.32
▸ GPR3 P46089 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2A6 P11509 1/20 0.32
▸ PLAU P00749 2/20 0.31
▸ F12 P00748 1/20 0.31
▸ NCF1 P14598 1/20 0.31
▸ NOS3 P29474 1/20 0.31
▸ NOS1 P29475 1/20 0.31
▸ NOS2 P35228 1/20 0.31
▸ BACE1 P56817 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ CASP6 P55212 1/20 0.31
▸ KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8424490 0.76 ATM (0.48) ATMPDPK1NPC1RAB9AKDM4E
SCHEMBL3535166 0.76 ATM (0.48) ATMPDPK1NPC1RAB9AKDM4E
SCHEMBL4559941 0.76 ATM (0.48) ATMPDPK1NPC1RAB9AKDM4E
SCHEMBL5259264 0.76 ATM (0.48) ATMPDPK1NPC1RAB9AKDM4E
SCHEMBL4288878 0.76 ATM (0.44) ATMPDPK1NPC1RAB9ABCL2
SCHEMBL5250885 0.73 ATM (0.45) ATMNPC1RAB9ABCL2KDM4E
SCHEMBL9769252 0.73 ATM (0.45) ATMPDPK1NPC1RAB9AKDM4E
SCHEMBL8423013 0.72 ATM (0.44) ATMNPC1RAB9ACYP1A2CYP2A6
SCHEMBL9769436 0.72 ATM (0.44) ATMNPC1RAB9A
SCHEMBL6081734 0.72 ATM (0.44) ATMNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109422697-A The method for synthesizing Quinazol derivative 南京理工大学 2019-03-05 — — CN claimed
US-11939335-B2 Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG 858 THERAPEUTICS, INC. (US) 2024-03-26 — — US disclosed
WO-2023224998-A1 INHIBITORS OF PARG 858 THERAPEUTICS, INC. (US) 2023-11-23 — — WO disclosed
US-20230374022-A1 INHIBITORS OF PARG 858 THERAPEUTICS, INC. 2023-11-23 — — US disclosed
EP-3618829-B1 QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES INC (US) 2023-06-07 — — EP disclosed
CN-110612100-B Quinazoline-pyridine derivatives for the treatment of diseases associated with cancer 艾库斯生物科学有限公司 2023-04-14 — — CN disclosed
EP-4023293-A1 2-AMINOQUINAZOLINONE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2022-07-06 — — EP disclosed
EP-4023293-A1 2-AMINOQUINAZOLINONE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2022-07-06 — — EP disclosed
CN-114650986-A 2-aminoquinazolinone derivatives 住友制药株式会社 2022-06-21 — — CN disclosed
CN-114650986-A 2-aminoquinazolinone derivatives 住友制药株式会社 2022-06-21 — — CN disclosed
CN-109422697-A The method for synthesizing Quinazol derivative 南京理工大学 2019-03-05 — — CN disclosed
WO-2018204661-A1 QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. (US) 2018-11-08 — — WO disclosed
EP-1885701-A2 2-AMINO-QUINAZ0LIN-5-ONES AS HSP90 INHIBITORS USEFUL IN TREATING PROLIFERATION DISEASES Novartis Vaccines and Diagnostics, Inc. (US) 2008-02-13 — — EP disclosed
EP-1618094-B1 SUBSTITUTED HETEROARYLS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INST FOR PHARM DISCOVERY INC (US) 2007-09-05 — — EP disclosed
US-20070027150-A1 2-Amino-quinazolin-5-ones NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2007-02-01 — — US disclosed
WO-2006113498-A2 2-AMINO-QUINAZ0LIN-5-ONES AS HSP90 INHIBITORS USEFUL IN TREATING PROLIFERATION DISEASES NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) 2006-10-26 — — WO disclosed
EP-1618094-A1 SUBSTITUTED HETEROARYLS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES The Institutes for Pharmaceutical Discovery, LLC (US) 2006-01-25 — — EP disclosed
US-20050009817-A1 Substituted heteroaryls INSTITUTES FOR PHARMACEUTICAL DISCOVERY, L.L.C. 2005-01-13 — — US disclosed
WO-2004099159-A1 SUBSTITUTED HETEROARYLS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) 2004-11-18 — — WO disclosed
US-6525061-B1 Combinatorial libraries for drug discovery;4-((6-bromo-4-oxo-1,4-dihydroquinazolin-2-yl)amino)b enzoic acid, WYETH 2003-02-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230374022-A1 INHIBITORS OF PARG PARG, PLG, SERPINB1 ATM 3147/4885PDPK1 1752/4885NPC1 941/4885
US-20050009817-A1 Substituted heteroaryls PTPRS, PTPRO, PTPRR ATM 979/4885PDPK1 220/4885NPC1 1488/4885
US-20070027150-A1 2-Amino-quinazolin-5-ones TK1, TK2, SLC1A5 ATM 1067/4885PDPK1 937/4885NPC1 865/4885
US-11939335-B2 Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG PARG, PTGIS, PLG ATM 4324/4885PDPK1 1051/4885NPC1 1470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.